Mizuho Securities Upgrades Jazz Pharmaceuticals (JAZZ) to Buy on Xyrem Settlements

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. LRCX
6. LVS
7. SAP
8. CSX
9. SPY
10. KNX

Go back to Mizuho Securities Upgrades Jazz Pharmaceuticals (JAZZ) to Buy on Xyrem Settlements

Jazz Pharma (JAZZ) EPS Miss Overshadowed By Settlements - UBS

May 11, 2016 9:05 AM EDT

UBS analyst, Marc Goodman, raised his PT on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $168 from $162 as high single digit revenue growth was basically in line with expectations but EPS of $2.26 fell short of consensus $2.30. The Street was a little low on spending but the analyst thinks investors will quickly look through the slight EPS miss because of the newly disclosed Xyrem patent settlements out to 2025, which is better than expected. The firm... More

Jazz Pharmaceuticals (JAZZ) Misses Q1 EPS by 5c; Guides In-Line

May 10, 2016 4:08 PM EDT

Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q1 EPS of $2.26, $0.05 worse than the analyst estimate of $2.31. Revenue for the quarter came in at $336 million versus the consensus estimate of $338.86 million.

"During the first quarter of 2016, we executed on our business model by delivering strong top-... More